Since its discovery in 2001, human metapneumovirus (hMPV) has been identified as an important cause of respiratory tract infection in young children, second only to the closely related respiratory syncytial virus (RSV). Clinical evidence suggests that hMPV is associated with acute exacerbations of asthma in both children and adults, and may play a role in initiating asthma development in children. Animal models have demonstrated that airway hyperresponsiveness (AHR) and inflammation are triggered following hMPV infection, and hMPV is able to persist in vivo by inhibiting innate immune responses and causing aberrant adaptive responses. In this review, we discuss the prevalence of hMPV infection in pediatric and adult populations and its potential role in asthma exacerbation. We also review recent advances made in animal models to determine immune responses following hMPV infection, and compare to what is known about RSV.
Skip Nav Destination
Article navigation
July 2017
-
Cover Image
Cover Image
This issue of Clinical Science showcases review articles covering kidney disease, the respiratory system, neurology and oxidative stress.
Review Article|
June 30 2017
Role of human metapneumovirus and respiratory syncytial virus in asthma exacerbations: where are we now?
Penny A. Rudd;
Penny A. Rudd
*
1Institute for Glycomics, Griffith University, Gold Coast Campus, QLD, Australia
Search for other works by this author on:
Belinda J. Thomas;
Belinda J. Thomas
*
2Monash Lung and Sleep, Monash Medical Centre, Melbourne, VIC, Australia
3Centre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research, Melbourne, VIC, Australia
4School of Clinical Sciences, Monash University, Melbourne, VIC, Australia
Search for other works by this author on:
Ali Zaid;
Ali Zaid
*
1Institute for Glycomics, Griffith University, Gold Coast Campus, QLD, Australia
Search for other works by this author on:
Martin MacDonald;
Martin MacDonald
2Monash Lung and Sleep, Monash Medical Centre, Melbourne, VIC, Australia
3Centre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research, Melbourne, VIC, Australia
4School of Clinical Sciences, Monash University, Melbourne, VIC, Australia
Search for other works by this author on:
Keiko Kan-o;
Keiko Kan-o
2Monash Lung and Sleep, Monash Medical Centre, Melbourne, VIC, Australia
3Centre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research, Melbourne, VIC, Australia
4School of Clinical Sciences, Monash University, Melbourne, VIC, Australia
Search for other works by this author on:
Michael S. Rolph;
Michael S. Rolph
1Institute for Glycomics, Griffith University, Gold Coast Campus, QLD, Australia
Search for other works by this author on:
Anand R. Soorneedi;
Anand R. Soorneedi
1Institute for Glycomics, Griffith University, Gold Coast Campus, QLD, Australia
Search for other works by this author on:
Philip G. Bardin;
Philip G. Bardin
2Monash Lung and Sleep, Monash Medical Centre, Melbourne, VIC, Australia
3Centre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research, Melbourne, VIC, Australia
4School of Clinical Sciences, Monash University, Melbourne, VIC, Australia
Search for other works by this author on:
Suresh Mahalingam
1Institute for Glycomics, Griffith University, Gold Coast Campus, QLD, Australia
Correspondence: Suresh Mahalingam ([email protected])
Search for other works by this author on:
Publisher: Portland Press Ltd
Received:
October 29 2016
Revision Received:
April 18 2017
Accepted:
May 02 2017
Online ISSN: 1470-8736
Print ISSN: 0143-5221
© 2017 The Author(s). Published by Portland Press Limited on behalf of the Biochemical Society
2017
Clin Sci (Lond) (2017) 131 (14): 1713–1721.
Article history
Received:
October 29 2016
Revision Received:
April 18 2017
Accepted:
May 02 2017
Citation
Penny A. Rudd, Belinda J. Thomas, Ali Zaid, Martin MacDonald, Keiko Kan-o, Michael S. Rolph, Anand R. Soorneedi, Philip G. Bardin, Suresh Mahalingam; Role of human metapneumovirus and respiratory syncytial virus in asthma exacerbations: where are we now?. Clin Sci (Lond) 15 July 2017; 131 (14): 1713–1721. doi: https://doi.org/10.1042/CS20160011
Download citation file:
Sign in
Don't already have an account? Register
Sign in to your personal account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.
Biochemical Society Member Sign in
Sign InSign in via your Institution
Sign in via your InstitutionGet Access To This Article
Open Access for all
We offer compliant routes for all authors from 2025. With library support, there will be no author nor reader charges in 5 journals. Check here |
![]() |